Answer
Yes, constipation was reported in galcanezumab migraine clinical trials in 1.0% of patients receiving 120 mg and 1.5% receiving 240 mg.
Sources for this answer
- Emgality 120 mg solution for injection in pre-filled penEli Lilly / Organon · emc · SmPC §4.8 Undesirable effects · Version 10Document updated
Sources checked